Core Insights - Cannara Biotech Inc. has successfully launched its vape cartridge category in Québec, achieving a 29.7% market share by retail sales value for November and December 2025 [1] - The company attained the 1 market share position in Québec for cannabis retail sales in December 2025, with a 14.7% share, reflecting a 100-basis point improvement month over month [2] Company Performance - The launch of the vape cartridge category has positioned Cannara as Canada's leading premium vape producer, with five of the 25 total SKUs approved [3] - The company has received strong consumer demand for its premium vape products, including new rosin vape cartridge offerings and leading live resin vapes [4] Stock Options and Governance - On December 31, 2025, Cannara's board approved the cancellation and re-issuance of 544,600 stock options due to an administrative oversight, ensuring compliance with its stock option plan [5][6] - The re-issued options include 500,000 with an exercise price of $1.44 expiring on August 27, 2035, and 15,000 with an exercise price of $1.80 expiring on November 20, 2032 [7] - The company is seeking shareholder approval to amend its Stock Option Plan and RSU Plan from rolling plans to fixed plans to enhance administrative clarity [8][9] Additional Announcements - The board approved the accelerated vesting of 15,000 restricted share units for a former director, ensuring compliance with the RSU Plan following his passing [11]